Regulation of tumour necrosis factor production by adrenal hormones in vivo: Insights into the antiinflammatory activity of rolipram

被引:44
作者
Pettipher, ER
Labasi, JM
Salter, ED
Stam, EJ
Cheng, JB
Griffiths, RJ
机构
[1] Department of Cancer, Immunology and Infectious Diseases, Ctrl. Research Division, Pfizer Inc., Groton
关键词
tumour necrosis factor; rolipram; inflammation; endotoxin;
D O I
10.1111/j.1476-5381.1996.tb15317.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The role of adrenal hormones in the regulation of the systemic and local production of tumour necrosis factor (TNF alpha) was examined in male Balb/c mice. 2 Intraperitoneal injection of 0.3 mg E. coli lipopolysaccharide (LPS, 0111:B4) led to high levels of circulating TNF alpha without stimulating TNF alpha production in the peritoneal cavity. Systemic production of TNF alpha in response to LPS was increased in adrenalectomized animals and in normal animals treated with the beta-adrenoceptor antagonist, propranolol, The glucocortoid antagonist, RU 486. did not modify systemic TNF alpha production. These results indicate that systemic TNF alpha production is regulated by adrenaline bur not by corticosterone. 3 When mice were primed with thioglycollate, TNF alpha was produced in the peritoneal cavity in response to low dose LPS (1 mu g) The levels of TNF alpha in the peritoneal cavity were not enhanced by adrenalectomy or by treatment with either propranolol or RU 456, indicating local production of TNF alpha in the peritoneal cavity is not regulated by adrenaline or corticosterone. 4 The phosphodiesterase type IV (PDE-IV) inhibitor, rolipram, inhibited both the systemic production of TNF alpha in response to high dose endotoxin (ED(50) = 1.3 mg kg(-1)) and the local production of TNF alpha in the peritoneal cavity in response to low dose endotoxin (ED(50)=9.1 mg kg(-1)). In adrenalectomized mice there was a slight reduction in the ability of rolipram to inhibit the systemic production of TNF alpha (ED(50)=3.3 mg kg(-1)) while the ability of rolipram to inhibit the local production of TNF alpha in the peritoneal cavity was virtually abolished (24% inhibition at 30 mg kg(-1)). The glucocorticoid antagonist, RU 486, also reduced the ability of rolipram to inhibit local TNF alpha production while propranolol was without effect. 5 Systemic treatment with rolipram increased the plasma concentrations of corticosterone in normal mice but not in adrenalectomized mice indicating that rolipram can cause adrenal stimulation in vivo. 6 In summary, these data indicate that systemic production of TNF alpha in response to high dose endotoxin is controlled differently from the local production of TNF alpha in response to ion dose endotoxin. The systemic production of TNF alpha is regulated by catecholamines, bur not by corticosterone, while the local production of TNF alpha in the peritoneal cavity is not regulated by basal levels of either catecholamines or corticosterone. 7 These data also show that the ability of rolipram to inhibit the local production of TNF alpha is dependent on the release of corticosterone from the adrenal glands.
引用
收藏
页码:1530 / 1534
页数:5
相关论文
共 26 条
[1]  
BAILLY S, 1990, Cytokine, V2, P205, DOI 10.1016/1043-4666(90)90017-N
[2]   PRIMARY SEQUENCE OF CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE ISOZYMES AND THE DESIGN OF SELECTIVE INHIBITORS [J].
BEAVO, JA ;
REIFSNYDER, DH .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1990, 11 (04) :150-155
[3]   ADRENALECTOMY SENSITIZES MICE TO THE LETHAL EFFECTS OF INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR [J].
BERTINI, R ;
BIANCHI, M ;
GHEZZI, P .
JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (05) :1708-1712
[4]   NEURO-ENDOCRINE REGULATION OF INVIVO CYTOKINE PRODUCTION AND EFFECTS .1. INVIVO REGULATORY NETWORKS INVOLVING THE NEURO-ENDOCRINE SYSTEM, INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR-ALPHA [J].
BUTLER, LD ;
LAYMAN, NK ;
RIEDL, PE ;
CAIN, RL ;
SHELLHAAS, J ;
EVANS, GF ;
ZUCKERMAN, SH .
JOURNAL OF NEUROIMMUNOLOGY, 1989, 24 (1-2) :143-153
[5]   INHIBITION OF EOSINOPHIL CYCLIC-NUCLEOTIDE PDE ACTIVITY AND OPSONISED ZYMOSAN-STIMULATED RESPIRATORY BURST BY TYPE-IV-SELECTIVE PDE INHIBITORS [J].
DENT, G ;
GIEMBYCZ, MA ;
RABE, KF ;
BARNES, PJ .
BRITISH JOURNAL OF PHARMACOLOGY, 1991, 103 (02) :1339-1346
[6]  
DERX B, 1993, LANCET, V342, P173
[7]   RANDOMIZED DOUBLE-BLIND COMPARISON OF CHIMERIC MONOCLONAL-ANTIBODY TO TUMOR-NECROSIS-FACTOR-ALPHA (CA2) VERSUS PLACEBO IN RHEUMATOID-ARTHRITIS [J].
ELLIOTT, MJ ;
MAINI, RN ;
FELDMANN, M ;
KALDEN, JR ;
ANTONI, C ;
SMOLEN, JS ;
LEEB, B ;
BREEDVELD, FC ;
MACFARLANE, JD ;
BIJL, H ;
WOODY, JN .
LANCET, 1994, 344 (8930) :1105-1110
[8]   A COMPARISON OF THE ACUTE INFLAMMATORY RESPONSE IN ADRENALECTOMIZED AND SHAM-OPERATED RATS [J].
FLOWER, RJ ;
PARENTE, L ;
PERSICO, P ;
SALMON, JA .
BRITISH JOURNAL OF PHARMACOLOGY, 1986, 87 (01) :57-62
[9]   EFFECT OF SELECTIVE PHOSPHODIESTERASE TYPE-IV INHIBITOR, ROLIPRAM, ON FLUID AND CELLULAR-PHASES OF INFLAMMATORY RESPONSE [J].
GRISWOLD, DE ;
WEBB, EF ;
BRETON, J ;
WHITE, JR ;
MARSHALL, PJ ;
TORPHY, TJ .
INFLAMMATION, 1993, 17 (03) :333-344
[10]  
HADLEY AJ, 1991, BRIT J PHARMACOL, V104, pP313